Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 5;14(19):4873. doi: 10.3390/cancers14194873

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Overall survival curves for patients in the New-FP and sorafenib groups. (A) New-FP (n = 418, red line) and sorafenib (n = 844, blue line), before propensity score matching. (B) New-FP (n = 198, red line) and sorafenib (n = 198, blue line), after propensity score matching. (C) Cohort 1 (no MVI or EHS), New-FP (n = 38, red line) and sorafenib (n = 38, blue line). (D) Cohort 2 (MVI with no EHS), New-FP (n = 78, red line), and sorafenib (n = 78, blue line). (E) Cohort 3 (EHS with no MVI), New-FP (n = 6, red line), and sorafenib (n = 6, blue line). (F) Cohort 4 (MVI and EHS), New-FP (n = 78, red line), and sorafenib (n = 78, blue line). HR, hazard ratio; MST, median survival time; New-FP, fine-powder cisplatin and 5-fluorouracil; EHS, extrahepatic spread; MVI, macrovascular invasion.

Overall survival curves for patients in the New-FP and sorafenib groups. (A) New-FP (n = 418, red line) and sorafenib (n = 844, blue line), before propensity score matching. (B) New-FP (n = 198, red line) and sorafenib (n = 198, blue line), after propensity score matching. (C) Cohort 1 (no MVI or EHS), New-FP (n = 38, red line) and sorafenib (n = 38, blue line). (D) Cohort 2 (MVI with no EHS), New-FP (n = 78, red line), and sorafenib (n = 78, blue line). (E) Cohort 3 (EHS with no MVI), New-FP (n = 6, red line), and sorafenib (n = 6, blue line). (F) Cohort 4 (MVI and EHS), New-FP (n = 78, red line), and sorafenib (n = 78, blue line). HR, hazard ratio; MST, median survival time; New-FP, fine-powder cisplatin and 5-fluorouracil; EHS, extrahepatic spread; MVI, macrovascular invasion.